President and Chief Scientific Officer Immorta Bio Inc miami beach, Florida, United States
Disclosure(s):
Thomas Ichim, PhD: No relevant disclosure to display
Introduction/Rationale: Senescent cells are known to possess inflammatory and degeneration-promoting properties. SenoVax(TM) is a dendritic cell based senolytic immunotherapy currently in development as a lung cancer therapeutic (FDA IND #30745) which mediates its antineoplastic effects by destruction of tumor surrounding senescent cells. We sought to assess whether SenoVax administration can enhance endogenous regenerative processes by clearance of senescent cells.
Methods: Induction of hematopoietic, hepatic and cardiac damage was performed using cyclosphophamide, carbon tetrachloride, and doxorubicin, respectively. Administration of SenoVax, or antibodies isolated from SenoVax treated mice was performed. Assessment of regeneration was quantified at a functional level, as well as by proliferation of progenitor cells. Enhancement of exogenously administered regenerative cells was also assessed.
Results: SenoVax or IgG antibodies from SenoVax immunized mice was capable of inducing enhanced hematopoiesis, reduction of liver failure enzymes, and preserve ejection fraction. Additionally, tissue specific progenitor cell expansion was observed. Administration of bone marrow mesenchymal stem cells synergized with SenoVax or antibodies from SenoVax immunized mice to enhance tissue regeneration after injury. No adverse effects or autoimmune reactions were observed.
Conclusion: In addition to its anti-neoplastic effects, SenoVax appear to induce a systemic regenerative response which would reduce adverse effects of conventional oncological agents as well as potentially make it an attractive candidate for the first "longevity promoting immunotherapy."
